Video

Dr. Bekaii-Saab on the Impact of Next-Generation Sequencing in mCRC

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses the utility of next-generation sequencing in metastatic colorectal cancer (mCRC).

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses the utility of next-generation sequencing in metastatic colorectal cancer (mCRC).

A couple of years ago, physicians would have likely said that genomic sequencing should be reserved for a select group of patients, says Bekaii-Saab. Now, every patient should get microsatellite instability (MSI) testing. Additionally, physicians now know that MSI is a surrogate biomarker for tumor mutational burden (TMB). All of these genomic platforms are showing that TMB has meaningful cutoffs, says Bekaii-Saab. Patients with high and potentially intermediate cutoffs respond to immunotherapy agents, whereas patients with low cutoffs do not. Now, TMB is being used to identify whether a patient should receive a PD-1 inhibitor or not.

For patients with KRAS and RAS mutations, testing is still limited, notes Bekaii-Saab, though identifying a BRAF mutation can help steer physicians toward the proper treatment. Physicians know that these patients have a worse prognosis with FOLFOX or FOLFOXIRI. Therefore, bevacizumab (Avastin) may be more suitable in the frontline setting.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma
Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Jun 19th 2025 - Jul 25th 2025

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity